Mundi hits back at Big Tobacco ban

Posted 15 July 2024 AM

Mundipharma has justified its decision to enter a new deal with inhaled medicines expert Vectura - owned by tobacco giant Philip Morris International (PMI) - insisting revenues generated  are reinvested into the "wellness and healthcare business" not cigarette sales.

The agreement to reformulate Mundipharma's asthma treatment Flutiform has outraged the Thoracic Society of ANZ (TSANZ) which has severed all ties with the pharma while its members, HCPs in the respiratory space, are planning to deprescribe the company's products where the health of their patients is not impacted.